Because both compounds are promoted for the same goal faster recovery it is easy to assume they share a mechanism
This estimate is derived from comparative pharmacology and peptide absorption literature rather than from direct human studies: What This Means If you take 10 mg orally, approximately 3.8 mg reaches systemic circulation The remaining 6.2 mg is metabolized by stomach acid, proteases, and first-pass liver metabolism before reaching the bloodstream However, this systemic bioavailability may not directly reflect brain bioavailability (the amount reaching the central nervous system) Brain Penetration A critical distinction: systemic bioavailability (what enters the blood) differs from brain bioavailability (what crosses the blood-brain barrier and reaches neural tissue)
However, studies using beta-3-adrenergic receptor knockout mice revealed a more complex picture: Long-term AOD-9604 treatment failed to produce weight loss in beta-3-AR knockout mice Acute administration still increased energy expenditure and fat oxidation in knockout mice This suggests beta-3-AR expression enhancement contributes to, but does not directly mediate, lipolytic effects The peptide appears to work through an unidentified receptor mechanism that subsequently influences beta-3-adrenergic signaling pathways
Long-term continuous use lacks safety data, so periodic breaks are generally recommended
The pre-dissolved solution is by nature less stable than the lyophilisate, and after the first opening of the applicator the stability window shortens
